Roth Capital analyst Kumaraguru Raja resumed coverage of Monopar Therapeutics with a Buy rating and $18 price target. Monopar has completed enrollment of over 130 patients in the company’s Phase 2b/3 trial for the prevention of severe oral mucositis, or SOM, and expects an interim analysis of the study of Validive in this indication in Q1 of 2023, Raja noted. In addition, the Camsirubicin Phase 1b trial data in advanced soft tissue sarcoma, or ASTS, patients has been "encouraging," the analyst said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MNPR:
- Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
- Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
- Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
- Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting